Skip to main content
AVIR
NASDAQ Life Sciences

Atea Signs $200M Hercules Term Loan, Draws $65M at Close

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$4.39
Mkt Cap
$345.682M
52W Low
$2.87
52W High
$6.45
52W Position info
53% above low
Off High info
32% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

AVIR sits 53% above its 52-week low of $2.87.

Summary

Atea entered a $200 million senior secured term loan with Hercules Capital, drawing $65 million at closing, with the rest contingent on Phase 3 C-FORWARD and BEM/RZR milestones. The debt is secured by substantially all assets, including intellectual property.


Key Events · Financing and Capital Events · AVIR

  • New $200M Hercules Term Loan

    A Loan and Security Agreement dated November 6, 2026 provides term loans of up to $200.0 million, maturing November 1, 2031.

  • $65M Drawn, Rest Milestone-Gated

    Tranche 1 of $65.0 million was drawn at closing; Tranche 2 (up to $35.0 million) requires Phase 3 C-FORWARD completion before a specified date in the second half of 2027, Tranche 3/4 (up to $35.0 million and $70.0 million) require financing and BEM/RZR milestones, and Tranche 5 (up to $30.0 million) is at lender discretion.

  • Cost and Collateral

    Interest is the greater of prime plus 2.35% or 9.35%, with a $650,000 initial upfront fee, 1.00% upfront fees on Tranche 2-5 advances, an end-of-term charge, and a security interest in substantially all assets including intellectual property.

  • Covenants Begin October 2027

    A minimum cash covenant is tested from October 1, 2027 (not tested when a market-cap requirement is met), and a performance covenant requiring BEM/RZR revenue or specified cash levels starts six months after FDA approval of BEM/RZR.


Analysis · AVIR · Life Sciences

Atea has secured a non-dilutive $200 million debt facility from Hercules Capital, swapping equity dilution for secured borrowing. Only $65 million is funded now; the remaining $135 million is gated behind Phase 3 C-FORWARD completion in the second half of 2027, BEM/RZR development and financing milestones, and lender discretion for the final $30 million. The cost is real: interest at the greater of prime plus 2.35% or 9.35%, a $650,000 upfront fee, 1.00% fees on later tranches, an end-of-term charge, and a lien on substantially all assets including intellectual property. Covenants bite from October 1, 2027, when a minimum cash test begins unless the company clears a market-cap threshold, and a revenue-or-cash performance covenant starts six months after any FDA approval of BEM/RZR. The structure ties the company's funding to the very clinical readout that determines its value.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AVIR was trading at $4.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $345.7M. The 52-week trading range was $2.87 to $6.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AVIR - Latest Insights

AVIR
Aug 12, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.06
Real-time Price: $4.39 info
Change: -$0.670 (-13%) info
Market Cap: $345.682M info
AVIR
Jul 28, 2026, 7:41 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $4.87
Real-time Price: $4.39 info
Change: -$0.480 (-10%) info
Market Cap: $345.682M info
AVIR
Jul 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.75
Real-time Price: $4.39 info
Change: -$0.362 (-8%) info
Market Cap: $345.682M info
AVIR
Jun 25, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.51
Real-time Price: $4.39 info
Change: -$0.120 (-3%) info
Market Cap: $345.682M info
AVIR
May 27, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.39
Real-time Price: $4.39 info
Change: $0 (0%) info
Market Cap: $345.682M info